1. Michelson Diagnostics Enters Reseller Agreement with Biotronics3D

    Michelson Diagnostics Enters Reseller Agreement with Biotronics3D

    Michelson will sell Biotronics3D’s software with its OCT products to deliver the most advanced 3D imaging for users to analyze and display 3D OCT data.

     

     

    (Orpington, UK) June 10, 2010 – Michelson Diagnostics, a leading innovator in Multi-Beam Optical Coherence Tomography (OCT) products for scientific research and healthcare imaging, has entered into a reseller agreement with UK-based Biotronics3D, a leading developer of innovative software applications for the diagnostic imaging industry.  Under the terms of the agreement Michelson, will market and sell Biotronics’ 3Dnet Suite with its VivoSight Scanner and EX1301 OCT Microscope.

     

    Biotronics’ 3Dnet Suite is an FDA-cleared medical imaging display tool with powerful abilities to view and analyze 3D DICOM datasets in real time. It is already widely used by hundreds of clinicians to examine CT, MRI and ultrasound images, and has the capability to segment and display renderings of 3D structures from low-contrast image sets. It can output reports in user-defined formats and can export to PACS, and provides full 3D measurement and image annotation tools.

     

    “We are delighted to be able to provide Biotronics’ advanced 3D imaging along with our OCT products,” says Jon Holmes, CEO of Michelson Diagnostics. “This will enable our users to display and analyze large 3D OCT datasets, to assist with making their clinical and scientific judgments more quickly and with greater power than current solutions in the market.”

     

    The agreement is the latest milestone Michelson Diagnostics has achieved in support of the company's global marketing strategy to deliver the most advanced skin imaging technology available for clinical and scientific analysis of skin. Earlier this year, Michelson received 510K clearance from the FDA for clinical use in the U.S. and previously received CE-Mark approval of its VivoSight Scanner for clinical use in Europe and non-clinical use worldwide.

     

    According to Dr. Haralambos Hatzakis, CEO at Biotronics "Our partnership with Michelson Diagnostics opens up a new user base for our 3D medical imaging software.  The power of Michelson’s Multi-Beam OCT coupled with 3D imaging provides new possibilities for the clinical user.” 

     Michelson Diagnostics Enters Reseller Agreement with Biotronics3DExample screenshot of Biotronics’ 3Dnet Suite displaying a 1000-slice VivoSight Multi-Beam OCT image of a malignant melanoma showing 3 orthogonal slices and 3D volume.

     

    About Biotronics3D

    Biotronics3D (www.biotronics3d.com), headquartered in London, UK, develops and markets innovative software applications for the diagnostic imaging industry. The company provides cutting edge software technologies to improve healthcare by better extracting diagnostic data and transforming it into usable information available at the point-of-care. Biotronics3D Ltd is an EN ISO 13485:2003 certified company and its flagship product, 3Dnet Suite, has received FDA 510K market clearance and it is CE marked.

     

    About Michelson Diagnostics

    Michelson Diagnostics was founded in 2006; it is privately owned and based in Kent, U.K.  The company develops imaging products using a technology called Multi-Beam Optical Coherence Tomography.  The technology provides real time images of up to 2mm into tissue with a resolution of better than 10 microns.

     

    The company’s products include the EX1301 OCT Microscope which is used by researchers in a variety of fields including genetics research, tissue engineering and industrial metrology; and the VivoSight OCT scanner which has CE and 510(k) clearance for use to aid clinical judgments in the field of dermatology. Applications of VivoSight include guiding skin cancer surgery and blood vessel imaging for assessing laser treatment effectiveness.

     

    Further Information

    Further information about Michelson Diagnostics is available on the Internet at http://www.md-ltd.co.uk/ or by email to enquiries@md-ltd.co.uk.

     

    For clinical use in the US FDA 510(k) K093520 applies:

    The VivoSight Topical OCT system is indicated for use in the two-dimensional, cross-sectional, real-time imaging of external tissues of the human body. This indicated use allows imaging of tissue microstructure, including skin, to aid trained and competent clinicians in their assessment of a patient's clinical conditions.

     

    US Federal law restricts this device to sale by or on the order of a physician.

     

    ______________________________________ 

    The Michelson Diagnostics logo and the VivoSight name are the trademarks of Michelson Diagnostics Ltd and are registered in the UK, the US & throughout the European Union.

     

    Media Contact

    Meghan J. O'Sullivan

    O'Sullivan Communications, Inc.

    42 Davis Road, Suite 1

    Acton, MA 01720

    978-264-0707x201

    meghan@ocmarketing.com

     

    Login to comment.

  1. Categories

    1. Applications:

      Art, Cardiology, Dentistry, Dermatology, Developmental Biology, Gastroenterology, Gynecology, Microscopy, NDE/NDT, Neurology, Oncology, Ophthalmology, Other Non-Medical, Otolaryngology, Pulmonology, Urology
    2. Business News:

      Acquisition, Clinical Trials, Funding, Other Business News, Partnership, Patents
    3. Technology:

      Broadband Sources, Probes, Tunable Sources
    4. Miscellaneous:

      Jobs & Studentships, Student Theses, Textbooks
  2. Quotes

    1. We are delighted to be able to provide Biotronics’ advanced 3D imaging along with our OCT products... This will enable our users to display and analyze large 3D OCT datasets, to assist with making their clinical and scientific judgments more quickly and with greater power than current solutions in the market.
  3. Topics Mentioned

  4. Authors